Discover and read the best of Twitter Threads about #ESTRO2021
Most recents (2)
1/ 🙏 patients, investigators and funders for
@TROGfightcancer 13.01 SAFRON II trial at #ESTRO21. n=90 pts with 133 pulmonary oligometastases, across 13 centers in 🇳🇿+🇦🇺. Median F/U = 3 years, randomization for single (SF) 28Gy vs 48Gy in 4fx (MF). #radonc #LCSM @PeterMacCC
@TROGfightcancer 13.01 SAFRON II trial at #ESTRO21. n=90 pts with 133 pulmonary oligometastases, across 13 centers in 🇳🇿+🇦🇺. Median F/U = 3 years, randomization for single (SF) 28Gy vs 48Gy in 4fx (MF). #radonc #LCSM @PeterMacCC
2/ No difference in SF vs MF. Both were safe (G3+ AEs were 5% MF v 3% SF), and effective - 2yr OS 85% MF v 88% SF (p=0.44), LC 83% MF v 73% SF (p=0.13). No diff. in DFS (median 13.2 MF v 14.3 SF, p=0.99). Mean time to systemic treatment ~29mo. SABR did not impact QoL measures
3/ Both SF and MF arms drove systemic immune activation
- ⬆️%CD4+FoxP3+ Tregs, ⬆️ %CTLA-4 and %PD-1 expressing CD4+, CD8+ and/or CD4-CD8- T cell subsets
- modestly ⬆️ % change of CD4+ T cell and CD8+ T cell subsets expressing PD-1 or TIGIT in the SF arm as compared to MF arm
- ⬆️%CD4+FoxP3+ Tregs, ⬆️ %CTLA-4 and %PD-1 expressing CD4+, CD8+ and/or CD4-CD8- T cell subsets
- modestly ⬆️ % change of CD4+ T cell and CD8+ T cell subsets expressing PD-1 or TIGIT in the SF arm as compared to MF arm
I cleared my schedule in anticipation of 2nd jab side-effects, and I’m aching all over with muscle pains, so it’s just the right time to channel my inner grumpy old man (I’m moving like one anyway).
In other words:
🔹Time to critique #ESTRO2021 abstracts! 🔹
#radonc #medphys
In other words:
🔹Time to critique #ESTRO2021 abstracts! 🔹
#radonc #medphys
Standard disclaimer:
I’m just one abstract reviewer. My opinions and dislikes may not be representative.
I’m not targeting any specific authors - so even if you feel this hits too close to home, it’s probably not you that I’m thinking of (five other people did the same!)
I’m just one abstract reviewer. My opinions and dislikes may not be representative.
I’m not targeting any specific authors - so even if you feel this hits too close to home, it’s probably not you that I’m thinking of (five other people did the same!)
I reviewed clinical track abstracts this year, while my previous involvement has been on the physics track. That's obviously colouring my experience.
(I am but a lowly physicist, etc, etc ... 😂)
(I am but a lowly physicist, etc, etc ... 😂)
